• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Verona Pharma halts development of inhaled antitussive

Verona Pharma has announced that it will stop development of its VRP700 inhaled antitussive after the drug failed to produce statistically significant reduction in cough frequency compared to placebo in a Phase 2a clinical trial. The trial evaluated the efficacy of a single dose of VRP700 in 20 idiopathic pulmonary fibrosis patients with severe chronic cough.

Earlier this year, Verona announced that it planned to raise up to £14 million for development of VRP700 and its lead drug, RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of COPD. The company says that it will now focus its efforts on RPL554.

Verona CEO Jan-Anders Karlsson commented, “These data are clearly disappointing and did not meet our expectations given the marked inhibition of coughing observed in a previous clinical trial with patients administered VRP700, albeit with a different underlying disease, ILD. It is possible that VRP700 works better in such patients or that more frequent dosing, for a longer time period, may be required to effectively suppress coughing in IPF patients. While we will not undertake any further in-house development of VRP700, we will comprehensively review the data from this study and explore opportunities to realize further value from this asset.”

Read the Verona press release.

Share

published on June 23, 2014

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews